XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and drug metabolism and pharmacokinetics (DMPK).
Clients from across the globe will be able to access highly experienced teams specialising in these core drug discovery disciplines. Both companies have outstanding drug discovery and development credentials. Together they are dedicated to delivering tailored solutions for clients and a more personalised service which ranges from target evaluation through to candidate nomination and predicted clinical pharmacokinetics and dose.
XenoGesis is a fast-growing provider of DMPK services, quantitative bioanalysis, in vitro pharmacology and modelling and simulation for human pharmacokinetic (PK) and dose prediction and the core team has a proven track record of delivery in drug discovery. BioAscent’s integrated drug discovery services are delivered by a team of expert biologists, medicinal chemists and compound management scientists co-located in state-of-the-art biology and chemistry laboratories.
Xenogesis and BioAscent have both received investment from BioCity Group and are based at BioCity Group sites in Nottingham (UK) and Glasgow (Scotland).